R: reaction time (TEG variable) ROTEM: rotational thromboelastometry TEG: thromboelastography

Introduction
There are currently 2 main systems, the TEG and ROTEM, utilizing viscoelastic technology to evaluate hemostasis. Most current laboratory and clinical research in human and veterinary medicine has been generated using these systems. The differences between these methodologies and the influence of pre-analytical and analytical variables on these assays have been presented in the previous three domains. The focus of this domain is to define existing variables and summarize available evidence regarding the reporting of data.
Evidence Summary
Worksheet Question: Should the TEG derived MA value be converted into the G value?
Conclusions: All 4 standard TEG/ROTEM variables should be universally reported, enabling post-hoc calculation of G if required. The reporting of G in addition to MA is encouraged to allow authors to evaluate and compare the clinical utility of both variables.
Summary of evidence:
The MA is the maximum amplitude, or width of divergence, of a tracing derived via TEG and represents the overall clot strength. The major contributors to MA are platelets, followed by fibrinogen, thrombin, factor XIII, and hematocrit. The shear elastic modulus, denoted by G, also represents the "global" clot strength and is derived from the MA using the following formula: G = (5000 X MA) / (100-MA). Since G is derived from the MA, it is a function of the same constituents. However, MA is a linear value expressed in mm, while G is an exponential transformation of MA expressed in dyn/cm 2 . Consider that a change in MA from 55 to 70 mm (a 30% change) represents a change in G from 5,500 to 11,666 dyn/cm 2 (a 112% increase). This distribution has been proposed to be more sensitive to hemostatic changes, especially as MA increases in size.
Twenty articles were identified which report G in addition to MA. Six studies were evaluated which reported both G and MA and included some comparison or discussion of the rationale for including the G value (LOE 3-6, Good-Poor). [1] [2] [3] [4] [5] [6] Of these 6 however, none directly addressed the worksheet question. In the 2 veterinary studies, both found MA and G to be relatively equal in the dog at identifying patients with clinical bleeding (LOE 4), 6 or patients with hypercoagulability induced by the administration of steroids (LOE 3). 2 As such a recommendation for using G in addition to, or in place of, MA cannot be made.
Future Directions: Studies directly comparing the clinical utility of each value against a non-TEG outcome measure in companion animals are needed.
Worksheet Question: Which TEG/ROTEM clot formation values should be reported in publications?
Conclusions:
We recommend that all 4 standard TEG/ROTEM variables are universally reported to enable meta-analyses to be conducted in future.
Summary of Evidence:
Few studies compare the variability or predictive value of the 4 standard TEG/ROTEM variables. Evidence from 9 studies (4 canine, 3 equine, 2 feline) (LOE 2-3, Good), [7] [8] [9] [10] [11] [12] [13] [14] [15] generally suggests that K time / CFT is the most variable of the 4 parameters, with  and MA / MCF generally the least variable. This might influence the individual predictive utility of the 4 parameters and may need to be considered during construction of diagnostic or therapeutic algorithms. No studies specifically compared the predictive value of K/CFT versus . A study on biological variation in coagulation parameters in dogs (LOE 3, Good), 15 suggests that all 4 TEG/ROTEM parameters provide useful information about hemostatic potential, as they have a low degree of individuality, making population reference intervals useful for TEG variables. 16 This was in contrast to clotting times, antithrombin, fibrinogen, and D-dimers which all have a high degree of individuality, rendering decisions based on population based reference intervals insensitive for those analytes.
Future Directions: Research comparing the predictive ability of individual TEG/ROTEM parameters is required. Until such studies are available, it seems prudent to report all TEG/ROTEM parameters to facilitate post-hoc evaluation to be performed and comparisons between studies to be made.
Worksheet Question: How should hypercoagulability be defined?
Conclusions: There is insufficient evidence to recommend how hypercoagulability should be defined in companion animals based on TEG/ROTEM parameters at this time. We suggest that individual studies report sufficient data on patients and institutional controls to enable definitions of hypercoagulability to be evaluated post-hoc. We recommend that all studies specifically report how hypercoagulability was defined. We recommend that all 4 standard TEG/ROTEM variables are universally reported to enable meta-analyses to be conducted in future. We recommend that at minimum, contemporaneous values for hematocrit, fibrinogen concentration and platelet count be reported in addition to TEG/ROTEM results.
By convention, shortened R (CF) or K (CFT), or increased  or MA (MCF), are considered consistent with hypercoagulability in companion animal species.
Nine articles specific to veterinary companion animals were identified in which a clear definition for "hypercoagulability" was presented (LOE 2-6, Fair-Poor). [17] [18] [19] [20] [21] [22] [23] [24] [25] It is also evident from multiple studies in companion animals and humans (LOE 2-6, Good-Fair), [26] [27] [28] [29] [30] [31] [32] that several hematologic variables, in particular hematocrit, fibrinogen concentration and platelet count, significantly affect the results of TEG/ROTEM assays.
As such, these values must be considered when defining hypercoagulability in particular patient populations, e.g. dogs with IMHA. Values for hematocrit, fibrinogen concentration and platelet count should be reported in addition to TEG/ROTEM values to enable the potential impact of these factors on the TEG/ROTEM results to be evaluated.
Future Studies: Further investigation, using a reliable thrombosis endpoint, in veterinary species to better define hypercoagulability based on TEG/ROTEM parameters is clearly required.
Worksheet Question: How should hypocoagulability be defined?
Conclusions: There is insufficient evidence to recommend how hypocoagulability should be defined in companion animals based on TEG/ROTEM parameters at this time. We suggest that individual studies report sufficient data on patients and controls to enable definitions of hypocoagulability to be evaluated post-hoc. We recommend that all studies specifically report how hypocoagulability was defined. We suggest that use of multiple TEG/ROTEM derived parameters in combination may increase specificity for identification of subsets of hypocoagulability. We recommend that all 4 standard TEG/ROTEM variables are universally reported to enable meta-analysis to be conducted in future. We recommend that values for hematocrit, fibrinogen concentration and platelet count be reported in addition to TEG/ROTEM results.
Evidence from three studies in dogs (LOE 2 and 4, Good), 6, 20, 25 and 1 study in horses (LOE 2, Good), 8 suggest that a suitable universal definition for hypocoagulability cannot be determined at this time. Present literature provides evidence that trends in variables indicating hypocoagulability include increased R/CT or K/CFT values and/or decreased MA/MCF or G/MCE values. Studies in non-target species (LOE 6, Good-Fair), 33, 34 suggest that combinations of TEG/ROTEM parameters to identify hypocoagulability may provide superior predictive ability for bleeding; and that ROC curve analysis of individual parameters to identify cut-off points with associated sensitivity and specificity values may improve our quantification of bleeding risk. Only one of the aforementioned veterinary studies prospectively evaluated how tissue factor (TF) activated TEG correlated to clinical signs of bleeding in dogs compared to a routine coagulation profile. 6 TEG correctly identified dogs with clinical signs of bleeding with a positive predictive value (PPV) of 89% and a negative predictive value (NPV) of 98%. Whereas, coagulation profiles had a PPV between 50-81% and a NPV between 92-93%, depending on the observer. It is noteworthy that underlying disease processes contributing to blood loss were varied. As previously mentioned, evidence from multiple studies in companion animals and humans (LOE 2-6, Good-Fair), [26] [27] [28] [29] [30] [31] [32] Conclusions: There is currently insufficient evidence to make a recommendation regarding use of CI in companion animals. We suggest that the CI equation derived for humans is not used for companion animals (CI = -0.245R + 0.0184K + 0.1655MA -0.0241 -5.0220).
We suggest that the CI equation derived for dogs may be considered for use in that species (CI = 0.1227R + 0.0092K + 0.1655MA -0.0241 -5.0220). 35 We recommend that all 4 standard TEG/ROTEM variables (R, K, α, MA / CT, CFT, , MCF) are universally reported to enable calculation of a coagulation index post-hoc if required.
Based on 5 articles reviewed (LOE 4-6, Fair-Poor), 32, [35] [36] [37] [38] of which none completely addressed the worksheet question, recommendation for using CI in addition to, or in place of, other TEG parameters cannot be made. Two veterinary studies utilized CI as a variable. One study involving IMHA in dogs found an association between a normal CI and decreased survival but was retrospective in nature and necropsies were not performed. 35 The CI formula used was reported to be canine in origin, produced with recalcified, non-activated, citrated whole blood, and although a review paper was referenced, the derivation was not provided. 39 The second study documented hypercoagulability in patients with renal failure and protein-losing nephropathy, with increased CI as a supportive variable. 32 The CI formula used was the human derivation produced with recalcified, non-activated, citrated whole blood.
Thus, although a canine specific coagulation index equation has been generated, the methodology for this derivation was not reported and the applicability or potential 
Worksheet Question: How should hyperfibrinolysis be defined?
Conclusions: There is insufficient evidence to recommend how hyperfibrinolysis should be defined in companion animals based on TEG/ROTEM parameters at this time. We suggest that individual studies report sufficient data on patients and controls to enable definitions of hyperfibrinolysis to be evaluated post-hoc. We suggest that the TEG variable (Ly30, Ly60, CL30, CL60) and the ROTEM variables (LI30, LI60, ML, LOT and LT) be universally reported to enable meta-analyses to be conducted in the future.
Summary of Evidence:
Only 1 veterinary publication was identified that was able to demonstrate the utility of TEG to document hyperfibrinolysis in companion animals (LOE 5, Poor). 40 In contrast, there is a large body of human literature which focuses on identifying hyperfibrinolysis in patients with trauma, brain surgery, liver transplantation, and other disease states using both TEG and ROTEM (LOE 6, Good-Poor). 10, 14, 15 do not include data pertinent to fibrinolysis. A study comparing 3 methods of activation for TEG in healthy cats (LOE 3, Good), 12 described median and range values for Ly30 and Ly60. As described in this manuscript, range values for Ly30 and Ly60 in normal cats reach as low as 0%. Similarly, reference intervals for Ly30 and Ly60 in dogs also reach 0% at the lower limit (LOE 5, Poor). 40 In the 1 study published in horses describing hypofibrinolysis in patients with acute gastrointestinal disease, reference intervals for Ly30 and CL30 extend to 0% and 100%, respectively (LOE 2, Fair). 41 As such, standard TEG and ROTEM assays appear to be unable to detect hypofibrinolysis in companion animals. The development of modified TEG models, which involve the addition of a fibrinolytic stress, e.g. tissue-plasminogen activator (t-PA), may better identify hypofibrinolysis. 66 A recent publication (LOE 2, Good) describes the usage of a t-PA-modified TEG analysis in a cohort of 20 dogs with diseases typically associated with thrombosis. 71 After applying t-PA, the lowest median lysis levels were in dogs with systemic inflammation and protein-losing disorders. Using a threshold below the lower end of the range of the healthy control group, more than 50% of the diseased dogs had Ly30 and Ly60 values consistent with hypofibrinolysis.
Future Directions: Studies are needed to correlate these variables with hypofibrinolytic states, documented with non-viscoelastic based technology, to determine the most clinically relevant data to report.
Worksheet Question: Should each center define its own TEG/ROTEM reference intervals?
How should TEG/ROTEM reference intervals be defined?
Conclusions:
We recommend that every center using TEG/ROTEM should establish its own reference interval using established veterinary clinical pathology guidelines. We recommend that reference intervals for TEG and ROTEM are not interchangeably used.
We recommend that only appropriately trained operators be involved in establishing reference intervals for TEG/ROTEM. We recommend that age and breed be considered when establishing reference intervals for TEG/ROTEM. We recommend that sample collection, sample handling and assay protocols be standardized when establishing reference intervals for TEG/ROTEM.
Summary of Evidence:
Multiple studies (LOE 2-6, Good-Fair), 10, 11, 14, 15, [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] Data collected from less than 20 animals should not be reported as reference intervals. 88 Although data collected from between 20-40 animals may be used for reference interval generation, they should be tested for normality and then appropriate robust or parametric methods used for RI calculation. 
